MedicalCountermeasures.gov can help you keep up-to-date on the latest developments in federal medical countermeasures activities, with information on public meetings and conferences, procurement and grant opportunities, strategies, reports, federal guidance on the development of medical countermeasures, and other announcements.
Provides links to information about public meetings, both upcoming and past, on issues pertaining to public health threats, both naturally occurring and manmade. Also included are links to online Meeting Libraries, such as the NIH Videocasting site.
Learn MoreProvides links to relevant federal guidance on issues related to the development medical countermeasures, including information on Emergency Use Authorization, the Animal Efficacy Rule, and the Select Agent Rule.
Federal Business Opportunities (FedBizOpps) is the single government point-of-entry (GPE) for Federal government procurement opportunities over $25,000. Commercial vendors seeking Federal markets for their products and services can search, monitor and retrieve opportunities solicited by the entire Federal contracting community through FedBizOpps.
Learn More
Provides links to relevant federal guidance on issues related to the development medical countermeasures, including information on Emergency Use Authorization, the Animal Efficacy Rule, and the Select Agent Rule.
Learn More
Provides links to sources of information useful to those involved in the research, development, and acquisition of medical countermeasures products, including Project Bioshield, and Public Health Emergency Medical Countermeasures Enterprise.
Learn More
The Federal Government has launched several major initiatives intended to accelerate basic research and development of vaccines, therapeutics, and diagnostics for naturally occurring and manmade threats.
Learn MoreLatest announcements related to medical countermeasures
Agreement expands efficient, rapid clinical trial of multiple COVID-19 drug candidates simultaneously.
Full AnnouncementThe Trump Administration, through the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD), will purchase an additional 100 million doses of COVID-19 vaccine candidate, called mRNA-1273, from Moderna.
Full Announcement